India, March 5 -- Jazz Pharmaceuticals Plc. (JAZZ), Wednesday announced a deal to acquire Chimerix Inc. (CMRX) for $8.55 per share in cash, or a total consideration of around $935 million.
Under the terms, Jazz will commence an all-cash tender offer to acquire all CMRX shares, whereby Chimerix shareholders will receive $8.55 per share in cash, reflecting around 72 percent premium based on the closing trading price on March 4.
Jazz expects to fund the transaction through existing cash and investments. The deal will be closed in the second-quarter of 2025.
Chimerix's lead clinical asset is Dordaviprone, a novel first-in-class small molecule treatment in development for H3 K27M-mutant diffuse glioma, a rare, high-grade brain tumor that impa...